Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00120718 · ClinicalTrials.gov registry record · Phase 2

The Effect of Fasudil on Vascular Function in Humans

A Phase 2 study, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target

NCT00120718: Completed Phase 2 study, sponsored by Brigham and Women's Hospital.

NCT00120718 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00120718, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

The purpose of the study is to evaluate how the rho kinase inhibitor, fasudil, affects vascular function in patients with atherosclerosis and hyperlipidemia.

Interventions

  • DRUG fasudil

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2002-06
Est. Completion 2007-01
Phase Phase 2
Brigham and Women's Hospital

937 total trials

What the finished NCT00120718 record still lists

NCT00120718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 1 intervention - of which fasudil is the first listed.

NCT00120718 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00120718 about?

NCT00120718 is a clinical study titled "The Effect of Fasudil on Vascular Function in Humans". The purpose of the study is to evaluate how the rho kinase inhibitor, fasudil, affects vascular function in patients with atherosclerosis and hyperlipidemia.

What is the current status of trial NCT00120718?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2002-06. Estimated completion is 2007-01.

What interventions are being tested in trial NCT00120718?

The interventions under investigation include: fasudil (DRUG).

Who is sponsoring clinical trial NCT00120718?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00120718's enrollment target sits among peer trials

60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00120718, the US trial registry maintained by the National Library of Medicine. NCT00120718 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.